Betagenon is now actively seeking partners for the further clinical development of O304 as a treatment for type 2 diabetes, diabetic kidney disease, chronic kidney disease and peripheral arterial disease.  Please contact;

Denise Goode, Licensing Strategist

denise.goode@betagenon.com

Mobile +44 (0) 77 110296 99